ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA  | Zendy

Babafemi Taiwo | Zendy; Lu Zheng | Zendy; Andrei Ştefănescu | Zendy; Amesika N. Nyaku | Zendy; Baiba Bezins | Zendy; Carole L. Wallis | Zendy; Catherine Godfrey | Zendy; Paul E. Sax | Zendy; Edward P. Acosta | Zendy; David W. Haas | Zendy; Kimberly Y. Smith | Zendy; Beverly E. Sha | Zendy; Cornelius Van Dam | Zendy; Roy M. Gulick | Zendy

Open Access

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

Author(s) -

Babafemi Taiwo,

Lu Zheng,

Andrei Ştefănescu,

Amesika N. Nyaku,

Baiba Bezins,

Carole L. Wallis,

Catherine Godfrey,

Paul E. Sax,

Edward P. Acosta,

David W. Haas,

Kimberly Y. Smith,

Beverly E. Sha,

Cornelius Van Dam,

Roy M. Gulick

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix1083

Subject(s) - dolutegravir , lamivudine , medicine , resistance mutation , adverse effect , virology , reverse transcriptase , reverse transcriptase inhibitor , viral load , virus , gastroenterology , rna , hepatitis b virus , biology , antiretroviral therapy , biochemistry , gene

Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research